

26 the possibility for recovered patients with positive IgG findings to be reinfected similarly
27 exists.

28 **Keywords:** COVID-19, SARS-CoV-2, reinfection, immunoglobulin G

29 **Introduction**

30 Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a novel
31 coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was
32 named so given the similarity of its symptoms to those induced by severe acute respiratory
33 syndrome [1]. Since the first reports of a viral pneumonia of unknown origin emerged from
34 China in late 2019, this disease has spread across the world, with new cases reported daily.
35 The clinical manifestations of COVID-19 range widely from asymptomatic to mild, moderate
36 and rapidly progressive severe (pneumonia) disease that can lead to death in some
37 individuals [2-4]. The moderate clinical symptoms of patients with COVID-19 include fever,
38 dyspnoea, fatigue, dry cough, myalgia and pneumonia. In severe cases, affected patients
39 may experience acute respiratory failure, septic shock and organ failure that might culminate
40 in death [5, 6].

41 Transmission of SARS-CoV-2 from infected people to others is suggested based on
42 epidemiology and clinical evidence [7, 8], with even asymptomatic infected individuals
43 believed to be capable of transmitting the virus [9, 10].

44 Infection by SARS-CoV-2 leads to a detectable immune response, but the susceptibility of
45 previously infected individuals to reinfection by SARS-CoV-2 is not well understood given the
46 brevity of the worldwide pandemic to date. Generally, infection results in the generation of
47 neutralising antibodies in patients [11] [12]. SARS-CoV2 has the capacity to escape innate
48 immune responses, which allows the pathogen to produce large numbers of copies in
49 primarily infected tissues, usually airway epithelia [13]. Principally, patients who recover from
50 infectious diseases are usually immunised henceforth against infection by the causative
51 virus; however, reinfection by respiratory viruses is extremely common among humans of all

52 ages due to these viruses' progressive evolution through RNA genome mutations that lead
53 to antigenic drift and immune escape. However, the complete mechanisms governing our
54 susceptibility to recurrent viral infections remain poorly understood [14, 15]. Although some
55 studies indicate the persistence of protective immunoglobulin IgG levels in the blood, saliva
56 and other body fluids for months after infection with SARS-CoV-2 [16, 17], limited numbers
57 of case studies of patients with COVID-19 have reported positive test results after the
58 disease symptoms had resolved and negative test results were recorded, supporting the
59 possibility of reinfection [18-20]. These reports included both patients with mild disease [21,
60 22]and others with more severe conditions [20, 23].

61 This study aimed to report an additional group of COVID-19 patients who were reinfected by
62 SARS-CoV-2 and argue that the IgG level is a potential marker of the reinfection risk.

63 **Materials and Methods**

64 ***Study population***

65 The study included a group of 829 patients admitted to Qala Hospital, Kalar, Kurdistan
66 region, Iraq from the last week of May until the middle of October.

67 ***Real-time reverse-transcription polymerase chain reaction (RT-PCR) assay for the*** 68 ***diagnosis of SARS-CoV-2***

69 Pharyngeal swabs were administered to extract SARS-CoV-2 RNA from each patient; then,
70 the total RNA was extracted using the AddPrep Viral Nucleic Acid Extraction Kit (Addbio Inc.,
71 Daejeon, South Korea). Next, The presence of the SARS-CoV-2 virus was detected by real-
72 time RT-PCR amplification of the SARS-CoV-2 open reading frame 1ab (ORF1ab) and
73 envelope (E) gene fragments. The amplification reactions were carried out with 10 µL of 2X
74 RT-PCR mastermix, 5 µL of primer/probe mix and 5 µL of template RNA for a final volume of
75 20 µL using the PowerChek SARS-CoV-2 Real-time PCR Kit (Kogenebiotech, Seoul,
76 Korea), described previously [24]. We followed the kit's instructions and adopted the
77 following thermocycler protocol: 50°C for 30 minutes and 95°C for 10 minutes, followed by

78 40 cycles of 95°C for 15 seconds and 60°C for one minute. When findings regarding the two
79 target genes (ORF1ab, E) were positive according to specific real-time RT-PCR, a sample
80 was defined as positive if the viral genome was detected at the cycle threshold value (Ct-
81 value) of 36.7 or less, while the Ct-value of greater 36.7 was defined as indicating a negative
82 test result or recovery (i.e., disappearance of signs and symptoms in a previously RT-PCR
83 positive patient).

84 ***Enzyme-linked Immunosorbent Assay***

85 A serum sample was collected from patients with a confirmed SARS-CoV-2 RT-PCR test
86 result just after their recovery.

87 The anti-SARS-CoV-2 IgG antibody level was assessed using a commercially available
88 SARS-CoV-2 IgG test kit (Pishtaz Teb Diagnostics, Tehran, Iran) targeting the nucleocapsid
89 (N) antigen of the SARS-CoV-2 virus. Sera were diluted 1:101. First, 10 µL of the specimen
90 together with 1,000 µL of the sample diluent was processed in a 96-well test kit. Then, 100
91 µL of each control serum and diluted specimens were placed into the appropriate well, with
92 the first two wells chosen as blanks and the next two chosen as negative control wells.
93 Positive controls were used as duplicates and the other wells were used for samples. Based
94 on the manufacturer's formula; the following cutoffs were applied: 1.1, positive; 0.9 to 1.1,
95 equivocal; and less than 0.9, negative.

96 ***Ethics declarations***


97 All methods were used in accordance with relevant guidelines and regulations. Also, we
98 confirmed that all experimental protocols were approved by the Ethics Licensing Committee
99 of the Kalar Technical Institute at the Sulaimani Polytechnic University (no. 02 on
100 01/08/2020). In addition, informed consent was obtained from all study participants or a
101 parent and/or legal guardian if the individual was younger than 18 years of age.

102

103 **Results**

104 Our study found that 87 patients tested negative for IgG specific to SARS-CoV-2 after
105 recovery among a population of 829 patients who were infected with SARS-CoV-2 for the
106 first time. Twenty-six patients (14 male and 12 female patients, aged 10–60 years old) were
107 reinfected after recovery; of these, 25 patients were in the IgG-negative group and only one
108 patient was IgG-positive (Figure 1).

109 Just after recovery, IgG antibodies against the SARS-CoV-2 were found in the serum of
110 most of the reinfected patients. Only one patient was reinfected even though his IgG result
111 remained positive after recovery from COVID-19 (Table 1). Most IgG-negative patients
112 presented with just a couple of signs of COVID-19, including fever (96%) and myalgia (68%)
113 and continued cough (< 15% cases), while reinfected patients suffered more signs including
114 fever (96%), myalgia (88%), continuous cough (88%) and loss of taste and smell together
115 (72%). In addition, after reinfection more than 95% of the reinfected COVID-19 patients had
116 been immunised as evidenced by IgG antibody induction. Surprisingly, there was no
117 detectable IgG concentration in a male patient who had most of the common signs and
118 symptoms of COVID-19 during both his first infection and reinfection. Also, a male patient
119 (no. 26 in Tables 1 and 2) showed serum IgG level of 5.87 s/ca against SARS-CoV-2 after
120 recovery but was reinfected 138 days later. Interestingly, the reinfection induced his immune
121 system to produce IgG level by amount (2.08 s/ca) less than the first infection. The
122 occurrence of reinfection in the group ranged from 26 to 138 days after recovery from the
123 initial infection (Table 2).



124

125 **Figure 1:** Patients with COVID-19. Among a total of 829 patients with COVID-19, 87 (10%) showed
126 negative findings for IgG specific to SARS-CoV-2. Twenty-five (3%) patients were reinfected during
127 the study period, while 62 (7%) patients remained healthy. A single patient with IgG positivity was
128 reinfected.(0%)**Table 1:** COVID-19 data of the 26 reinfected patients in this study

129

130

131

132

133

134

135

136

137

138

No.	Gender	Age range (years)	Infected COVID-19 patients		Reinfected COVID-19 patients	
			Date of positive RT-PCR result for SARS-CoV-2 infection	IgG (s/ca) after recovery	Reinfection after (days of) recovery	IgG (s/ca) after Recovery
1	M	20s	Jul	Negative	89	6.7
2	F	30s	Aug	Negative	55	10.3
3	M	20s	Sep	Negative	26	7.3
4	F	10s	Aug	Negative	37	9.3
5	M	40s	Aug	Negative	55	15.5
6	F	40s	Sep	Negative	39	10.7
7	F	40s	Aug	Negative	42	11.3
8	M	50s	Aug	Negative	46	10.3
9	F	50s	Aug	Negative	53	5.35
10	F	40s	Aug	Negative	35	11.2
11	M	40s	Jul	Negative	76	7.22
12	F	40s	Aug	Negative	45	11.2
13	M	40s	Aug	Negative	34	7.4
14	M	40s	Aug	Negative	50	12.51
15	F	40s	Aug	Negative	42	11.5
16	M	40s	Aug	Negative	62	7.11
17	F	40s	Aug	Negative	49	8.37
18	M	40s	Jul	Negative	72	5.11
19	F	30s	Aug	Negative	40	10.3
20	M	30s	Aug	Negative	59	6.3
21	M	40s	Aug	Negative	42	Negative
22	M	50s	Aug	Negative	53	9.3
23	M	20s	Aug	Negative	49	7.25
24	F	40s	Aug	Negative	52	6.21
25	F	20s	Aug	Negative	54	11.9
26	M	30s	May	5.87	138	2.08

139 .

140

141

142

143

144

145

146 **Table 2:** Sign and symptoms among all reinfected patients during both infection and reinfection

No.	Gender	Age range (years)	First COVID-19 infection					COVID-19 reinfection				
			Fever	LTS	SB	Myalgia	Cough	Fever	LTS	SB	Myalgia	Cough
1	M	20s										
2	F	30s										
3	M	20s										
4	F	10s										
5	M	40s										
6	F	40s										
7	F	40s										
8	M	50s										
9	F	50s										
10	F	40s										
11	M	40s										
12	F	40s										
13	M	40s										
14	M	40s										
15	F	40s										
16	M	40s										
17	F	40s										
18	M	40s										
19	F	30s										
20	M	30s										
21	M	40s										
22	M	50s										
23	M	20s										
24	F	40s										
25	F	20s										
26	M	30s										

147 Dark area, positive; light area, negative.

148 **Discussion**

149 Approximately 90% of recovered COVID-19 patients produce a detectable level of
 150 IgG [25]. In our study, among 829 infected cases, 742 IgG-positive recovered
 151 patients were identified. The duration and viral magnitude can play a crucial role in
 152 inducing the immune system to produce an adequate IgG level [26-28], which can be
 153 an indicator of the severity of the disease [29]. Therefore, it may be postulated that
 154 those patients who recovered from SARS-CoV-2 infection with IgG negativity in this
 155 study were exposed to a lesser amount of viral antigen.

156 The degree of protective immunity conferred by prior infection and the possibility of
157 reinfection by SARS-CoV-2 is not well understood [20]. This study reports that
158 around 10% of recovered COVID-19 patients showed no detectable IgG
159 concentration after recovery and prior to their reinfection. A pair of studies from Hong
160 Kong and Ecuador have reported SARS-CoV-2 reinfection in two IgG-negative
161 patients who previously recovered from COVID-19 [21, 22]. The IgG level appears to
162 be associated with the severity of the illness during the first infection; studies have
163 shown that patients with mild symptoms had no/lower antibody titers as compared
164 with those patients with more severe symptoms [21, 29, 30]. In our study, the degree
165 of disease severity in the reinfection period was worse in most patients than that
166 during the first instance of COVID-19. A similar case study was reported in a 46-
167 year-old male Ecuadorian patient [23]. This contradicts with the findings of a couple
168 of case studies in which patients were asymptomatic during their reinfection period
169 but were symptomatic during their first infection [21, 22]. The increase in disease
170 severity in reinfected patients can be due to a high viral load or a change in virus
171 virulence, which might have facilitated reinfection [20, 31]. The lack of a detectable
172 level of IgG against SARS-CoV-2 during the infection period in mild or asymptomatic
173 patients possibly makes them more susceptible to the reinfection. Therefore, in the
174 current study, it is believed that the vast majority of patients who showed detectable
175 levels of IgG after COVID-19 were thus protected from reinfection, even though the
176 time period of the immunity conferred by IgG against SARS-CoV-2 has not been
177 concluded yet [21]. Unexpectedly, a male patient was reinfected with COVID-19
178 without inducing IgG production a second time, which raises the question of possible
179 reinfection for a third time. Also, another male patient had detectable amounts of IgG
180 during his first infection and was reinfected after 138 days with no symptoms. That

181 may be due to a decrease in his IgG level as time passed as studies have suggested
182 neutralizing IgG levels start to decrease at six to 13 weeks after infection resolution
183 [29, 32, 33]. Mysteriously, the reinfection in the aforementioned patient induced a low
184 level of a detectable serum IgG concentration. This raises questions concerning the
185 presence of adaptive immunity in COVID-19 patients.

186 **Conclusion**

187 To conclude, a lack of IgG in patients who have recovered from COVID-19 may lead
188 some to become infected. IgG production possibly indicates the severity of the signs
189 and symptoms of COVID-19. Also, IgG levels against SARS-CoV-2 may decrease
190 with time. Further studies are needed to consider the efficiency and sustainability of
191 IgG, which are likely to play a vital role in the success of the COVID-19 vaccine
192 industry.

193 **Author contributions**

194 AMA performed lab work. KMA, MHF, HMT and HMR contributed to writing and
195 preparing the manuscript.

196 **Conflict of interests**

197 We are authors of the article titled ‘Severe Acute Respiratory Syndrome Coronavirus
198 2 Reinfection in Patients Negative for Immunoglobulin G Following Recovery from
199 Coronavirus Disease 2019.’ We confirm that we do not have any conflicts of interest
200 to report for the submitted manuscript.

201 **Funding**

202 No funding covered the work

203

204 References

- 205 [1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
206 Pneumonia in China, 2019. *New England Journal of Medicine*. 2020;382:727-33.
- 207 [2] Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. *BMJ*.
208 2020;369:m1375.
- 209 [3] Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 Antibody
210 Seroprevalence in Santa Clara County, California. *medRxiv*. 2020:2020.04.14.20062463.
- 211 [4] Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. *International Journal of*
212 *Infectious Diseases*. 2020;94:44-8.
- 213 [5] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019
214 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395:497-506.
- 215 [6] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of
216 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*.
217 2020;395:507-13.
- 218 [7] Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia
219 associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a
220 family cluster. *The Lancet*. 2020;395:514-23.
- 221 [8] Yu P, Zhu J, Zhang Z, Han Y. A Familial Cluster of Infection Associated With the 2019 Novel
222 Coronavirus Indicating Possible Person-to-Person Transmission During the Incubation Period. *The*
223 *Journal of Infectious Diseases*. 2020;221:1757-61.
- 224 [9] Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper
225 Respiratory Specimens of Infected Patients. *New England Journal of Medicine*. 2020;382:1177-9.
- 226 [10] Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-
227 nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine*.
228 2020;382:970-1.
- 229 [11] Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-
230 CoV-2 infection. *Nature*. 2020;584:115-9.
- 231 [12] Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 pneumonia: A report of two cases.
232 *Journal of Infection*. 2020;81:e72-e3.
- 233 [13] Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment
234 options. *Clinical Immunology*. 2020;215:108448.
- 235 [14] Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. *Critical Care*.
236 2019;23:303.
- 237 [15] Nogales A, L DeDiego M. Host single nucleotide polymorphisms modulating influenza A virus
238 disease in humans. *Pathogens*. 2019;8:168.
- 239 [16] Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of
240 human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19
241 patients. *Science Immunology*. 2020;5:eabe0367.
- 242 [17] Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva
243 antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Science Immunology*.
244 2020;5:eabe5511.
- 245 [18] Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in
246 COVID-19: A case report. *International Journal of Infectious Diseases*. 2020;93:297-9.
- 247 [19] Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dynamic profile of RT-PCR findings from 301
248 COVID-19 patients in Wuhan, China: A descriptive study. *Journal of Clinical Virology*.
249 2020;127:104346.
- 250 [20] Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence
251 for reinfection with SARS-CoV-2: a case study. *The Lancet Infectious Diseases*.

- 252 [21] To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. Coronavirus Disease 2019
253 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome
254 Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. *Clinical Infectious Diseases*. 2020.
255 [22] Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E,
256 et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. *Clinical Infectious*
257 *Diseases*. 2020.
258 [23] Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Marquez S, Gutierrez B, Rojas-Silva P, et al.
259 COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in
260 South America. First Confirmed Event in South America(September 3, 2020). 2020.
261 [24] Ali KM, Ali AM, Tawfeeq HM, Figueredo G, Rostam HM. Hypoalbuminemia in Severe COVID-19
262 Post Recovery Patients. 2020.
263 [25] ECDC. Reinfection with SARS-CoV-2: considerations for public health response. European Centre
264 for Disease Prevention and Control; 2020.
265 [26] Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of
266 COVID-19. *The Lancet Infectious Diseases*. 2020;20:656-7.
267 [27] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult
268 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395:1054-
269 62.
270 [28] Fourati S, Hue S, Pawlotsky J-M, Mekontso-Dessap A, de Prost N. SARS-CoV-2 viral loads and
271 serum IgA/IgG immune responses in critically ill COVID-19 patients. *Intensive Care Medicine*.
272 2020;46:1781-3.
273 [29] Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment
274 of asymptomatic SARS-CoV-2 infections. *Nature Medicine*. 2020;26:1200-4.
275 [30] Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody
276 responses to SARS-CoV-2 in convalescent individuals. *Nature*. 2020;584:437-42.
277 [31] Guallar MP, Meiriño R, Donat-Vargas C, Corral O, Juvé N, Soriano V. Inoculum at the time of
278 SARS-CoV-2 exposure and risk of disease severity. *International Journal of Infectious Diseases*.
279 2020;97:290-2.
280 [32] Wang X, Guo X, Xin Q, Pan Y, Li J, Chu Y, et al. Neutralizing Antibodies Responses to SARS-CoV-2
281 in COVID-19 Inpatients and Convalescent Patients. *medRxiv*. 2020:2020.04.15.20065623.
282 [33] Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics
283 of SARS-CoV-2 through the postpandemic period. *Science*. 2020;368:860-8.

284